Journey with AxxessBio:
Stay informed with our latest news, press releases and shared milestones

GENCEBOK® (caffeine citrate) for apnoea of prematurity is now approved in Singapore

AxxessBio is pleased to share that GENCEBOK® (caffeine citrate) 10 MG/ML SOLUTION FOR INFUSION has been approved by the Health Sciences Authority (HSA) Singapore for apnoea of prematurity.

  • Treatment of primary apnoea of premature newborns

GENCEBOK® is the first caffeine citrate approved in Singapore for above indication.

GENCEBOK® was also granted the European Marketing Authorization (EMA) in Aug 2020.

GENCEBOK® has the following features providing the convenience of administration and accessibility:

  • Solution can be used intravenously and orally
  • Optimal concentration for maintenance dose
  • Pharmaceutical-grade single-use ampoule
  • Room temperature storage
  • Long shelf life up to 3 years

Caffeine citrate is recommended by the World Health Organization for the treatment of apnoea in preterm infants <37 weeks’ gestation.

*Please refer to the local package insert for full prescribing information.

Interested in Partnering Up?

At AxxessBio, we are continuously looking for partnerships to bring new innovative therapies for patients all around Asia